MedTrace Logo

Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery

NCT04209218 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1988

Last updated 2025-07-31

No results posted yet for this study

Summary

Surgery is the front-line therapy for non-small cell lung cancer (NSCLC) but postoperative complications remains high and patients' long-term outcome is still challenging. In addition to surgery, anesthetic management particularly intraoperative blood pressure management and use of dexamethasone may affect patients' early and long-term outcomes after surgery for NSCLC. This study aims to investigate the impact of intraoperative blood pressure management and dexamethasone administration on early and long-term outcomes in patients undergoing surgery for lung cancer.

Conditions

Interventions

DRUG

Dexamethasone

Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.

OTHER

Targeted blood pressure management

Blood pressure is maintained within ±10% from baseline.

DRUG

Placebo

Placebo (2 ml normal saline) is administered before anesthesia induction.

OTHER

Routine blood presure management

Blood pressure is maintained according to routine practice.

Sponsors & Collaborators

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Dong-Xin Wang, MD, PhD · Peking University First Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-07
Primary Completion
2026-12-31
Completion
2029-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04209218 on ClinicalTrials.gov